proair setback disappoint diversif
keep thesi intact
delay gener proair clearli disappoint impress
quick disclosur expect compani effort frame impact
product result adjust model conserv assum
proair launch see meaning impact valuat thesi
compani given broad portfolio span private-label over-the-counter us brand
over-the-counter europ ou market infant nutrit anim health product
well gener pharma product continu faith abil deliv
grow revenu product launch outsid proair continu execut
new manag team maintain buy rate pt
proair come anticip disclos confer
call fda may compani determin would receiv approv
gener proair review cycl clear reason
potenti complet respons letter fda review timelin turnaround
preclud potenti approv launch time previou
impact clearli telegraph compani may earn
report initi guid clearli indic time
impact ep potenti proair launch despit development setback
encourag transpar regard impact one gener product
speed disclos potenti
develop inhal gener hard conserv move back proair
launch estim evidenc gener advair develop proair
extrem difficult develop gener inhal product certain
timelin potenti proair launch move launch estim
reduc revenu ep estim accordingli given
initi ep guid reduct rel minor view
materi chang thesi stock
price close busi may
perrigo compani plc focus develop
distribut private-label gener brand over-the-counter
prescript drug private-label nutrit product
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
chang estim
follow announc anticip delay gener proair launch
adjust revenu ep estim
figur chang revenu ep estim
price target deriv dcf consid wacc
risk rate price target
long-term chca growth depend rx-to-otc shift new categori
usual drive low-single-digit growth consum health america
chca busi though increas privat label uptak off-set somewhat retail
price pressur believ signific sustain growth chca busi
driven addit categori switch prescript over-the-counter condit
littl control brand pharma compani fda
resist move statin topic pain nsaid overact bladder treatment
erectil dysfunct product migrain product asthma inhal ophthalm
allergi dry-ey treatment over-the-counter could see pressur chca segment
despit domin share chca addit competitor start gain
long held domin share private-label over-the-counter market recent
over-the-counter switch seen steadi competit tradit prescript gener
compani seek gain traction over-the-counter retail typic assumpt
share given pl over-the-counter market longer guarante
believ continu increment competit could significantli slow perrigo
consum health intern chci busi may prove drag
take correct action segment follow challeng
belgian busi believ growth could slow segment follow brexit
potenti fx challeng continu restructur busi
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst
whose contact inform appear front page report
million usd except per share non-gaaprevenueconsum healthcar healthcar profit oper expensescost ipr oper expensestysabri chang expens expense/ incom sale invest -- -- -- -- -- -loss extinguish non-oper net incomeincom tax analysisbas per share share figur perrigo dcf model
million usd except per share healthcar healthcar depreci amort exclud chang growth estim period long-term period net debt share outstand compani
